Dassault Systèmes: Still Waiting For Growth And Margin To Inflect Up

Dassault Systemes (DASTY) reported mixed Q2 2025 results, with 6% constant currency revenue growth in line with expectations, but an adjusted EBIT margin miss at 29.3% versus a 29.7-29.9% target, primarily due to cost inflation. While 3DEXPERIENCE software revenue accelerated 20% and core manufacturing segments demonstrated resilience, overall growth quality was constrained by persistent flatness in Life Sciences and weakness in Centric PLM. This uneven performance maintains a 'show-me' dynamic for the stock, leading to a continued hold rating as the market awaits recovery in underperforming segments and improved cost scalability to justify a multiple re-rating.

Analysis

Dassault Systemes reported mixed Q2 2025 results, where in-line revenue growth was overshadowed by a significant profitability miss and uneven performance across its portfolio. Total revenue increased 6% year-over-year in constant currency, supported by a 10% rise in subscription-based licensing. However, this growth was not broad-based; strong performance in Industrial Innovation (up 9% y/y) was counteracted by a flat result in Life Sciences and weak 4% growth in Mainstream Innovation. The primary concern stemmed from the adjusted EBIT margin, which at 29.3% fell below the guided range of 29.7-29.9%, a decline attributed to cost inflation that challenges the expected operating leverage from the subscription model. A key positive is the accelerating adoption of the strategic 3DEXPERIENCE platform, with its revenue growth quickening to 20% y/y and its share of software revenue increasing to 41%. Core manufacturing verticals also demonstrated resilience, with Aerospace & Defense growing 15% y/y in the first half, buoyed by long-cycle investments. Nevertheless, the persistent weakness in the Life Sciences and Centric PLM segments places a cap on consolidated growth and keeps the stock in a 'show-me' state, reflected in a forward P/E of approximately 21x, below its historical average of 25x.

Key Decisions for Investors

• Given the balance between the strong long-term potential of the 3DEXPERIENCE platform and the immediate pressures on margins and key segments, a neutral 'hold' stance is warranted until a clear positive inflection is demonstrated.
• Investors should closely monitor the Life Sciences segment for the guided recovery in the second half of 2025, as a turnaround here would serve as a primary catalyst for a potential stock re-rating.
• Scrutinize future earnings reports for evidence of improved cost control and margin expansion, as the recent miss has put the company's operating leverage narrative into question.
• While the valuation is below its historical average, suggesting a potential long-term entry point, investors must weigh this against the current lack of near-term catalysts and the risk of continued range-bound performance.